VacZine Analytics releases MarketVIEW: Opioid use disorder vaccines


01-02-2018

A brand-new research study: "MarketVIEW: Opioid use disorder (OUD) vaccines report” has recently been added to VacZine Analytics portfolio offering.

Opioid use disorder (OUD) is a chronic relapsing condition characterized by a problematic pattern of heavy, uncontrolled opioid use. In the United States, OUD usually involves consumption of either: licensed prescription painkillers such as oxycodone, hydrocodone, or illicit street drugs such as heroin and synthetic analogues such as fentanyl/carfentanyl. Recently, the US prevalence of OUD has reached epidemic levels. During 2015, approximately 2.1m and 0.59m individuals had OUD associated with prescription painkillers and heroin respectively (0.8 and 0.2 per 100 persons, CDC figures, self-reported, >12 yrs) (1). Past year use numbers are as high as 13-15m people (US) (1). OUD has caused a massive surge in the number of US hospitalizations, emergency department visits and overdose deaths. The 2016 US figure of ~42,000 opioid overdose deaths was the highest on record (2). OUD is now lowering the life-expectancy of the average American (3) and costs the US economy billions of dollars each year in both direct and indirect costs (4). OUD is a global issue.

Medication-assisted therapy (MAT) treatment involving methadone (OTP only), buprenorphine and naltrexone, in combination with psychosocial counselling, can stabilize the opioid user either through detoxification or maintenance strategies. However, these treatments have strong safety considerations and are associated with high relapse or discontinuation. Moreover, only a fraction of opioid users initiate therapy. New interventions are desperately needed. Opioid hapten-based conjugated vaccine technologies have shown promising effects in preclinical models (5,6). Ideally, an OUD vaccine should be broad spectrum, multivalent and block both the addictive and toxic effects of opioids thereby decreasing patient relapse, possibly in combination with existing therapies. An OUD vaccine could be safer, have a longer efficacy duration and thereby better compliance than existing small molecule therapies. Simplicity and lower perceived stigma might drive more people into treatment programs.

MarketVIEW: opioid use disorder vaccines (CAT No: VAMV078), published February 2018 consists of a detailed Executive presentation (~140 .pdf slides) and comprehensive MS-Excel workbook (.xls) which forecast the potential commercial value/volume of a putative OUD vaccine across 8 major western markets from 2030. Three scenarios have been modelled which explore vaccine uptake at various access points along the patient treatment continuum. A thorough situation review (global epidemiology) is included along with a discussion of current treatments, prevention strategies, major R&D initiatives, and competitive environment. Vaccine technologies are reviewed along with TPP generation, pricing considerations and all modelling assumptions. This study is designed to inform any party wishing to understand and seek justification for the business case of this important vaccine. 

For more information please contact info@vaczine-analytics.com or www.vaczine-analytics.com

VacZine Analytics, world-leading supplier of vaccine-related commercial analyses is a trading division of Assay Advantage Ltd (UK Company No: 5807728, UK VAT: 883584084)

VacZine Analytics will make a charitable donation to local drug addiction/counselling programs on each sale of this study.

References:

  1. US Centers For Disease Control and Prevention. Drug Surveillance Report. Available at: https://www.cdc.gov/drugoverdose/pdf/pubs/2017-cdc-drug-surveillance-rep... Accessed January 2018
  2. US Centers For Disease Control and Prevention. Drug overdose death data.  Available at: https://www.cdc.gov/drugoverdose/data/statedeaths.html Accessed January 2018
  3. Economic Aspects of the Opioid Crisis. Testimony before the Joint Economic Committee of the United States Congress. Sir Angus Deaton. June 8, 2017
  4. Florence CS et al. The economic burden of prescription opioid overdose, abuse and dependence in the United States, 2013. Med Care. 2016; 54(10): 901-6
  5. Bremer PT et al (2017) Development of a clinically-viable heroin vaccine. J Am Chem Soc 139: 8601 – 861
  6. Sulima A et al. A Stable Heroin Analogue That Can Serve as a Vaccine Hapten to Induce Antibodies That Block the Effects of Heroin and Its Metabolites in Rodents and That Cross-React Immunologically with Related Drugs of Abuse. J. Med. Chem., 2018, 61 (1), pp 329–343
 

VacZine Analytics is an established strategic research publisher based in the United Kingdom.

VacZine Analytics Ltd (Assay Advantage)